1
|
Zorn KE, Cunningham AM, Meyer AE, Carlson KS, Rao S. Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology. Cancers (Basel) 2023; 15:1443. [PMID: 36900239 PMCID: PMC10000481 DOI: 10.3390/cancers15051443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2022] [Revised: 02/14/2023] [Accepted: 02/21/2023] [Indexed: 03/03/2023] Open
Abstract
Myeloid sarcomas (MS), commonly referred to as chloromas, are extramedullary tumors of acute myeloid leukemia (AML) with varying incidence and influence on outcomes. Pediatric MS has both a higher incidence and unique clinical presentation, cytogenetic profile, and set of risk factors compared to adult patients. Optimal treatment remains undefined, yet allogeneic hematopoietic stem cell transplantation (allo-HSCT) and epigenetic reprogramming in children are potential therapies. Importantly, the biology of MS development is poorly understood; however, cell-cell interactions, epigenetic dysregulation, cytokine signaling, and angiogenesis all appear to play key roles. This review describes pediatric-specific MS literature and the current state of knowledge about the biological determinants that drive MS development. While the significance of MS remains controversial, the pediatric experience provides an opportunity to investigate mechanisms of disease development to improve patient outcomes. This brings the hope of better understanding MS as a distinct disease entity deserving directed therapeutic approaches.
Collapse
Affiliation(s)
- Kristin E. Zorn
- Department of Pediatrics, Division of Hematology/Oncology/Transplantation, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- Versiti Blood Research Institute, Milwaukee, WI 53226, USA
| | | | | | - Karen Sue Carlson
- Versiti Blood Research Institute, Milwaukee, WI 53226, USA
- Department of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | - Sridhar Rao
- Department of Pediatrics, Division of Hematology/Oncology/Transplantation, Medical College of Wisconsin, Milwaukee, WI 53226, USA
- Versiti Blood Research Institute, Milwaukee, WI 53226, USA
- Department of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| |
Collapse
|
2
|
Yazdani Z, Mousavi Z, Moradabadi A, Hassanshahi G. Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia. Cancer Manag Res 2020; 12:2155-2165. [PMID: 32273755 PMCID: PMC7102884 DOI: 10.2147/cmar.s234883] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2019] [Accepted: 03/03/2020] [Indexed: 12/11/2022] Open
Abstract
Acute myeloid leukemia (AML) is defined as an aggressive disorder which is described by accumulation of immature malignant cells into the bone marrow. Chemokine-receptor axes are defined as factors involved in AML pathogenesis and prognosis. The chemokine receptor CXCR4 along with its ligand, CXCL12 fit in important players that are actively involved in the cross-talk between leukemia cells and bone marrow microenvironment. Therefore, according to the above introductory comments, in this review article, we have focused on delineating some parts played by CXCL12/CXCR4 axis in various aspects of AML malignancy. Targeting both leukemic and stromal cell interaction is nowadays accepted as a wide and attractive strategy for improving the outcome of treatment in AML in a non-cell autonomous manner. This strategy might be employed in a wide variety of AML patients regardless of their causative mutations. In addition to several potential targets involved in the disruption of malignant leukemic cells from their specific protective niches, compounds which interfere with CXCL12/CXCR4 axis have also been explored in multiple early-phase established clinical trials. Moreover, extensive research programs are exploring novel leading mechanisms for leukemia-stromal interactions that appear to find out novel therapeutic targets within the near future.
Collapse
Affiliation(s)
- Zinat Yazdani
- Department of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran
| | - Zahra Mousavi
- Department of Hematology and Medical Laboratory Sciences, Iranshahr University of Medical Sciences, Iranshahr, Iran
| | - Alireza Moradabadi
- Department of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran
| | - Gholamhossein Hassanshahi
- Department of Hematology and Blood Banking, Kerman University of Medical Sciences, Kerman, Iran.,Molecular Medicine Research Center, Institute of Basic Medical Sciences Research, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
| |
Collapse
|
3
|
Lee JP, Bae JB, Yang SH, Cha RH, Seong EY, Park YJ, Ha J, Park MH, Paik JH, Kim YS. Genetic predisposition of donors affects the allograft outcome in kidney transplantation; polymorphisms of stromal-derived factor-1 and CXC receptor 4. PLoS One 2011; 6:e16710. [PMID: 21304904 PMCID: PMC3033398 DOI: 10.1371/journal.pone.0016710] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2010] [Accepted: 01/11/2011] [Indexed: 12/11/2022] Open
Abstract
Genetic interaction between donor and recipient may dictate the impending
responses after transplantation. In this study, we evaluated the role of the
genetic predispositions of stromal-derived factor-1 (SDF1) [rs1801157
(G>A)] and CXC receptor 4 (CXCR4) [rs2228014 (C>T)] on
renal allograft outcomes. A total of 335 pairs of recipients and donors were
enrolled. Biopsy-proven acute rejection (BPAR) and long-term graft survival were
traced. Despite similar allele frequencies between donors and recipients, minor
allele of SDF1 rs1801157 (GA+AA) from donor, not from recipients, has a
protective effect on the development of BPAR compared to wild type donor (GG)
(P = 0.005). Adjustment for multiple
covariates did not affect this result (odds ratio 0.39, 95% C.I
0.20–0.76, P = 0.006). CXCR4
rs2228014 polymorphisms from donor or recipient did not affect the incidence of
acute rejection. SDF1 was differentially expressed in renal tubular epithelium
with acute rejection according to genetic variations of donor rs1801157 showing
higher expressions in the grafts from GG donors. Contrary to the development of
BPAR, the presence of minor allele rs1801157 A, especially homozygocity,
predisposed poor graft survival
(P = 0.001). This association was
significant after adjusting for several risk factors (hazard ratio 3.01;
95% C.I = 1.19–7.60;
P = 0.020). The allelic variation of
recipients, however, was not associated with graft loss. A donor-derived genetic
polymorphism of SDF1 has influenced the graft outcome. Thus, the genetic
predisposition of donor should be carefully considered in transplantation.
Collapse
Affiliation(s)
- Jung Pyo Lee
- Seoul National University Kidney Research
Institute, Seoul, Korea
| | - Jong Bin Bae
- Seoul National University College of Medicine,
Seoul, Korea
| | - Seung Hee Yang
- Seoul National University Kidney Research
Institute, Seoul, Korea
| | - Ran-hui Cha
- Department of Internal Medicine, Seoul
National University College of Medicine, Seoul, Korea
| | - Eun Young Seong
- Department of Internal Medicine, Pusan
National University School of Medicine, Busan, Korea
| | - Yang Jin Park
- Department of Surgery, Seoul National
University College of Medicine, Seoul, Korea
| | - Jongwon Ha
- Department of Surgery, Seoul National
University College of Medicine, Seoul, Korea
| | - Myoung Hee Park
- Department of Laboratory Medicine, Seoul
National University College of Medicine and Clinical Research Institute, Seoul,
Korea
| | - Jin Ho Paik
- Department of Pathology, Seoul National
University College of Medicine, Seoul, Korea
| | - Yon Su Kim
- Seoul National University Kidney Research
Institute, Seoul, Korea
- Department of Internal Medicine, Seoul
National University College of Medicine, Seoul, Korea
- * E-mail:
| |
Collapse
|
4
|
Affiliation(s)
- Sarah R Vaiselbuh
- Pediatric Hemato-Oncology & Stem Cell Transplantation, Cohen Children's Medical Center, New Hyde Park, New York 11040, USA.
| |
Collapse
|
5
|
The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010; 341:149-72. [PMID: 20376612 DOI: 10.1007/82_2010_25] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Acute myelogenous leukemia (AML) is a bone marrow disease in which the leukemic cells show constitutive release of a wide range of CCL and CXCL chemokines and express several chemokine receptors. The AML cell release of various chemokines is often correlated and three release clusters have been identified: CCL2-4/CXCL1/8, CCL5/CXCL9-11, and CCL13/17/22/24/CXCL5. CXCL8 is the chemokine usually released at highest levels. Based on their overall constitutive release profile, patients can be classified into distinct subsets that differ in their T cell chemotaxis towards the leukemic cells. The release profile is modified by hypoxia, differentiation status, pharmacological interventions, and T cell cytokine responses. The best investigated single chemokine in AML is CXCL12 that binds to CXCR4. CXCL12/CXCR4 is important in leukemogenesis through regulation of AML cell migration, and CXCR4 expression is an adverse prognostic factor for patient survival after chemotherapy. Even though AML cells usually release high levels of several chemokines, there is no general increase of serum chemokine levels in these patients and the levels are also influenced by patient age, disease status, chemotherapy regimen, and complicating infections. However, serum CXCL8 levels seem to partly reflect the leukemic cell burden in AML. Specific chemokine inhibitors are currently being developed, although redundancy and pleiotropy of the chemokine system are obstacles in drug development.
Collapse
|